Johnson & Johnson JNJ

Johnson & Johnson posted FY revenue of $93B with a -0.9% YoY, signaling a stable base but no accelerating growth. Our econometric model suggests growth is anchored in the commercial engine—SG&A-driven market access and pricing—rather than an outsized R&D push or a rapid product-cycle ramp. SG&A ROI of $3.64 per $1 implies each dollar of SG&A spend translates into roughly $3.64 of revenue, underscoring that scale and execution across a diversified portfolio are the main growth drivers at this stage. The holdout was about -9.9% (predicted $22.1B vs actual $24.6B), highlighting modest forecast reliability and suggesting catalysts like launches or reimbursement shifts aren’t fully captured; growth remains exposed to pricing/regulatory risk and mix shifts across pharma, devices, and consumer health.